Moderators: TAB78
Search This Board: 
Created: 01/13/2012 06:58:36 PM - Followers: 356 - Board type: Free - Posts Today: 0

Existing therapeutics have been unable to halt disease progression or extend life in a meaningful way

Cerebain’s novel device approach is supported by research and patient outcomes

Clinical evidence supports the Company’s working approach, that omentum stimulation improves cognitive function in patients with dementia, including Alzheimer’s Disease

Minimally invasive, one-time device implantation will overcome challenges associated with previous omentum stimulation procedures that are highly invasive

Patent-pending technology with broad applicability

Recent scientific breakthroughs regarding the potential identification of gene-specific protein increases prior to on-set of symptoms, could compliment our work

Early diagnosis is key to helping patients maintain quality of life http://www.nia.nih.gov/alzheimers/publication/alzheimers-disease-genetics-fact-sheet

Experienced management and advisory teams with the expertise to move the clinical program forward efficiently and effectively

http://www.cerebain.com/

https://www.facebook.com/CerebainBiotech

https://twitter.com/cerebainbiotech

 

News History

Disclosures and Filings

OTCQB Certification

https://backend.otcmarkets.com/otcapi/company/financial-report/180313/content
 

Corporate Leadership

Eric Clemons, President and CEO
e-mail:  clemons@cerebain.com

Mr. Clemons has a long history building and growing companies across multiple industries. Prior to assuming leadership of Cerebain, he served as President and Chief Operating Officer for GTC Telecom Corp, a publicly traded Nevada Corporation that operated out of Costa Mesa, CA. During his tenure, Mr. Clemons was instrumental in growing the company’s annual revenues from $500,000 per year to over $17 million per year.

It was Cerebain technology, which offers a completely new way of approaching the development of an effective Alzheimer’s disease treatment that captured Mr. Clemons’ imagination, triggering his move into the life sciences arena.

“While there have been some very recent key learnings in the Alzheimer’s treatment space, the fact is that the disease remains the only top ten killer in the United States with no effective treatments currently available and no way to halt or slow progression,” Clemons said. “We are hopeful that our device, which will focus on the impact of omental stimulation and cognitive function in Alzheimer’s Disease patients, can change that.”

Wesley Tate – former - Chief Financial Officer
e-mail:  wtate@cerebain.com

Prior to joining Cerebain Biotech, Mr. Tate was the owner of Strategic Business Associates, a Tennessee-based consultancy offering business management and growth services to start-up and early-stage companies.

Over the course of his career Mr. Tate has held key managerial positions at both healthcare and telecoms companies. This includes Chief Financial Officer for HST Global, Inc., a development-stage biotechnology company located in Virginia; and Executive Vice President and Chief Operating Officer for InnerLight Inc., a life science company located in Utah.

Mr. Tate received his Bachelor of Science degree from the University of Tennessee, Knoxville, with majors in Finance and Psychology, and earned his Masters of Business Administration from the University of Tennessee, Knoxville, with concentrations in Finance and Management.

He is proud to have served his country as a member of the United States Army.

Mr. Tate resigned from Cerebain in July of 2019, he did however agree to assist in any way possible during the transition period, as best as anyone has been able to determine, he is still functioning at CBBT is some sort or manner.

Cerebain engaged with NMS Consulting  - 

""NMS Consulting will also advise Cerebain on a corporate restructuring and cost savings plan, under which it will identify opportunities to optimize operations, drive efficiency and reduce costs.""

 

https://www.businesswire.com/news/home/20181204005563/en/Cerebain-Initiates-Repositioning-Review-Business-Corporate-Strategic

NMS Consulting - http://www.nms-consulting.com/

Global Advisors - http://www.globalviewadvisors.com/our-clients/

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cerebain’s Technology

Patent-pending technology has allowed for the development of a medical device that can
be implanted using a minimally invasive procedure.

Once implanted via what will probably be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method.

Cerebain has a manufacturing agreement with Sonos Medical, a trusted and reliable medical device supplier.

Clinical Trials

The Company is now in the process of preparing for initial clinical trials that will most likely occur at multiple medical centers in Europe.
 

Potential for a Personalized Approach to
Treatment for Alzheimer’s Disease Patients

As clinical trials are conducted and variables are put into play (e.g., frequency of stimulation, duration, location, etc.,) we may find that individuals respond differently and require individualized treatment plans. Cerebain’s device can potentially provide this, making our ability to positively impact the lives of as many Alzheimer’s Disease patients as possible.


In 2010 Cerebain Biotech licensed patent-pending technology for an implantable device that stimulates the omentum, and can be adjusted non-invasively to account for a range of factors, including frequency, strength of stimulation and location.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

International Patent License

"" International Application Number PCT/US2009/031462 (published as WO 2009/0094340), titled “Omentum and Use Thereof”;""

Patent is a 20 Year Internatinal Agreement; ""Subject to the payment of fees under this title, such grant shall be for a term beginning on the date on which the patent issues and ending 20 years from the date on which the application for the patent was filed in the United States or""
https://www.law.cornell.edu/uscode/text/35/154

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FDA -SRO List - Detail

DUNS NUMBER: 962489683
BUSINESS NAME: Cerebain Biotech Corp.
COUNTRY NAME:  USA
TICKER SYMBOL:  CBBT
EXCHANGE NAME: OTHER OTC Market

Last Updated: 11/20/2020 
https://www.accessdata.fda.gov/scripts/sda/sdDetailNavigation.cfm?sd=srolist&id=B49046C05F3E740FE0530D98C30A4787&rownum=1

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Reuters Does Report on Cerebain Biotech Corp. https://twitter.com/SamKnows7/status/1237803256845414402

Technology

Cerebain has a patent-pending device that is implanted in the omentum, a protective layer of skin that protects the abdominal organs. The device is designed to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias, including Alzheimer’s Disease.

Cerebain will evaluate the effect of omental stimulation at different intervals and levels of stimulation to determine the device’s ability to slow, stop or reverse the progression of Alzheimer’s Disease on patients.

About the Omentum

Generally described as a protective layer in the abdomen, the omentum covers the intestines, hangs on to the stomach and can be lifted like a flap. While the omentum is not a well-recognized body part, it can play important healing and protective roles for its host.

Protection: The omentum has abundant blood and lymphatic vessels, and can move flexibly throughout the abdomen to protect organs from threat and injury.

Healing: Additionally, it contains the largest supply of stem cells in the adult body. Because of its abundant blood supply, surgeons have long used the omentum to patch internal injuries sustained to other parts of the body.


Publications on the Omentum and it's Regenerative Powers

"Omentum a powerful biological source in regenerative surgery

""Regen Ther. 2019 Dec; 11: 182–191.    Published online 2019 Aug 8.""
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6700267/#

"Thinking Inside and Outside the Box: Intra- and Extra-Abdominal Use of the Amazing Omentum" Mar 8, 2019 
Bonnie Grambow Campbell, DVM, PhD, DACVS
College of Veterinary Medicine
Washington State University, Pullman, WA
https://www.vetfolio.com/learn/article/thinking-inside-and-outside-the-box-intra-and-extra-abdominal-use-of-the-amazing-omentum

 

 

About the Omentum

 

Omental Transposition to the Brain for Alzheimer's Disease

First published: 17 December 2006        https://doi.org/10.1111/j.1749-6632.1997.tb48483.x     Citations: 13

Abstract

ABSTRACT: Omental transposition (OT) to revascularize the brain was first performed in animals in the late 1960s, where it was shown that blood vessels originating from the omentum crossed through the omental-cerebral interface prior to developing into large-sized vessels that penetrated directly and deeply into the underlying brain. The additional cerebral blood flow coming from the omentum was of sufficient volume to protect an animal's brain from cerebral infarction even in the presence of middle cerebral artery ligation. It was also learned that the omentum was a rich source for neurotransmitters and omentum-derived nerve growth substance. OT to the brain is now being done for a variety of conditions which include strokes, TIAs, epilepsy, and Parkinson's disease. Of recent interest is the published information that OT may play some role in Alzheimer's disease (AD). The placement of the omentum on an AD brain has led to a profound decrease in senile plaque formation. The omentum may ultimately prove to be beneficial in reversing or at least stabilizing the dementia associated with the devastation of AD.

https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1749-6632.1997.tb48483.x

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Omental transposition for Alzheimer’s disease

Pages 103-108 | Accepted 01 Sep 1995, Published online: 21 Jul 2016       https://doi.org/10.1080/01616412.1996.11740387

 

A patient with Alzheimer’s disease of long standing was treated with omental transposition to his brain. The rational for the procedure was to use the omentum to increase cerebral blood flow and to augment cholinergic neurotransmission activity. The patient improved for a year following surgery but after that time slowly began to decline neurologically and cognitively. However; according to Alzheimers specialists who have followed the patient pre and post- operatively he still maintains, 2.5 years after surgery a higher level of performance than expected. There is theoretical and now a clinical suggestion that the omentum might play some role in the treatment of Alzheimer’s disease. In view of the devastating nature of, the disease, it seems reasonable to suggest that a limited controlled study be carried out to support or negate the benefit of the operation. [Neurol Res 1996; 18: 103–108]

https://www.tandfonline.com/doi/abs/10.1080/01616412.1996.11740387

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Cerebain Biotech Signs Letter of Intent with PKG, Inc.

Cerebain Biotech acquire assets of PKG

Aug. 25, 2020 9:07 AM ET|About: Cerebain Biotech Corp. (CBBT)|By: Pranav Ghumatkar, SA News Editor 

Cerebain Biotech (OTCPK:CBBT) has entered into a letter of intent to purchase the assets of PKG.

With complete in-house vertical integration, PKG provides its customers with all of their product development needs from R&D, design & development, product testing and end of life product support and transitioning.

https://seekingalpha.com/news/3608531-cerebain-biotech-acquire-assets-of-pkg?utm_source=otcmarkets&utm_medium=referral

 

NMS Consulting Selected as Strategic Advisor to Cerebain Biotech Corp. for Acquisition Project

BEVERLY HILLS, CA / ACCESSWIRE / October 6, 2020 / NMS Consulting, Inc. ("NMS") is pleased to announce that it has been selected as strategic advisor by Cerebain Biotech Cop. (OTCPINK:CBBT) ("Cerebain") for its planned acquisition of PKG, Inc. ("PKG").

https://nmsconsulting.com/wp-content/uploads/2018/12/Logo-Full-Color-1.png

--------------------------------------------------------------------------------------------------------------------------------------------------------

About PKG

http://www.pkguis.com/

A CONTRACT DESIGN MANUFACTURER FOR
MEDICALGOVERNMENTAEROSPACE, AND INDUSTRIAL
INTERFACE SOLUTIONS.

http://www.pkguis.com/what-we-do

https://www.linkedin.com/company/pkg-user-interface-solutions

Pkg Inc.https://twitter.com/PKG_UIS

JonFrank Director of Sales PKG Inc.https://twitter.com/PKGUIS

------------------------------------------------------------------------------------------------------------------------------------------------
PKG Inc.’s CEO Excited With the Potential Acquisition by Cerebain Biotech

COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”

Eric Clemons, CEO of Cerebain, added "We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations."

About Cerebain Biotech Corp. Cerebain Biotech Corp. (OTC: CBBT) is a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The corporate vision is based on these positive clinical observations. Visit us at www.cerebain.com or connect with us on Twitter and Facebook to learn more.

About PKG Inc. PKG, Inc. was established in 1989 and is a privately held corporation based out of Meridian, ID. PKG, Inc. specializes in contract design, development, and manufacturing of system-level devices with expertise in human-machine interfaces. With experience in medical, aerospace, government, and industrial products, PKG helps to raise your company to the next level by leveraging our skills in engineering and technology integration across your product lines. With a complete in-house vertical integration of expertise, services, manufacturing processes, and technologies, PKG provides our customers with all of their product development and manufacturing needs. In addition to our expertise of system level devices and human machine interfaces, PKG also offers incubation and acceleration services for startup business and entrepreneurs.

------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

PKG Inc.’s CEO Excited With the Potential Acquisition by Cerebain Biotech

September 03, 2020 08:30 AM Eastern Daylight Time

COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) previously announced, on August 25, 2020, that it had entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG).

“We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations.”

https://abs.twimg.com/errors/logo23x19.png";) -1px center no-repeat; float: left; font-size: 16px; margin: 10px 0px; padding: 3px 3px 3px 28px; border: none; outline: none medium !important;" rel="nofollow ugc">Tweet this

Almir Garibovic, CEO of PKG Inc., stated “After 30 years in business, PKG, Inc. is thrilled that we have entered into a letter of intent to be acquired by Cerebain Biotech Corp. We are excited by this partnership because of our complementary strengths and it will enable us to fulfill our vision and values, while we continue to provide our customers with innovative design, technologies and manufacturing capabilities as never before.”

Eric Clemons, CEO of Cerebain, added "We are committed to evaluating both Companies strategic core competencies to enhance value for our shareholders while maintaining our focus on the continued development of Cerebain’s device for the treatment of Alzheimer’s Disease as well as aggressively managing PKG’s current operations."

https://www.businesswire.com/news/home/20200903005085/en/PKG-Inc.%E2%80%99s-CEO-Excited-Potential-Acquisition-Cerebain

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TNS New Potential Home Run Report Available Now

September 03 2020 - 08:35AM
InvestorsHub NewsWire


New York, NY – September 3, 2020 -- InvestorsHub NewsWire – Traders News Source, a leading independent equity research and corporate access firm focused on small cap growth companies issues new research reports.

Cerebain Biotech Corp. (OTCPINK: CBBT) a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution, has entered into a Letter of Intent to purchase the assets of PKG, Inc. (PKG). PKG, Inc. is a leading contract design, developer, and manufacturing company for system-level devices with expertise in human-machine interfaces focusing on healthcare, industrial, aerospace and government products.

------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

PKG REGISTERS WITH FDA AND ANNOUNCES MANUFACTURING COMPLIANCE CERTIFICATION FROM TÜV SÜD

PKG, a privately-owned contract manufacturing and engineering company developing high-end medical and aerospace equipment, announced their registration with the FDA as an establishment producing medical personal
protection equipment (PPE), such as surgical masks. PKG also announced the completion of the transfer of its ISO 13485:2016 and ISO 9001:2015 compliance certificates
that encompasses the design, development, and production of its devices. 

 

The TÜV SÜD ISO 13485:2016 certification is for the contract design, development, and manufacture of non-implantable OEM system-level medical systems, subassemblies, and components for the areas of diagnostics,
imaging, patient treatment, monitoring, and surgical devices. This certification is from TÜV SÜD, one of the few organizations recognized as a designated body under the new European Medical Device Regulation (MDR).
It enables PKG to leverage its research, development, and manufacturing strengths for multiple new products addressing novel indications as we advance. TÜV SÜD’s MDR designation
will also ensure the continuity of regulatory compliance and support post-MDR implementation per European Union Directives on medical devices.

To Red More -> https://www.pkguis.com/news-content/2020/9/30/pkg-registers-with-fda-and-announces-manufacturing-compliance-certification-from-tv-sd

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PKG Inc. enters into an agreement with Adventus Ventures to finalize the development and manufacturing of the next-generation products for Allevion Therapeutics and Pressao Medical

PKG Inc.,

MERIDIAN, Idaho, October 5th, 2020 

PKG Inc. is pleased to announce a joint agreement with Adventus Venture, a medical device incubator, to finalize development and manufacturing plans for two companies in their portfolio: Allevion Therapeutics and Pressao Medical. PKG Inc. has been in business for over 30 years, developing complex and high-tech products for healthcare, aerospace, industrial, and government markets. In addition to the primary business model that supports Fortune 500 customers, PKG has heavily invested in developing infrastructure for the incubation and acceleration of start-up companies in the medical device sector.

To read more -> https://www.pkguis.com/news-content/2020/9/30/pkg-registers-with-fda-and-announces-manufacturing-compliance-certification-from-tv-sd-wglmd 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MICROCAP DAILY

The Rise of Cerebain Biotech Corp OTCMKTS: CBBT) PKG LOI - October 7 2020

Cerebain Biotech Corp OTCMKTS: CBBT) has been running up the charts in recent weeks quickly attracting legions of shareholders and emerging as a volume leader in small caps as the Company
is in the process of acquiring PKG, Inc., a developer, and manufacturing company for system-level devices with expertise in human-machine interfaces
focusing on healthcare, industrial, aerospace and government products.


Read More ->  https://microcapdaily.com/the-rise-of-cerebain-biotech-corp-otcmkts-cbbt-pkg-loi/128112/

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Tweet from Eric

October 12 2020
Dear PKG Customer
.

I would like to thank all of you for the support and business you have provided to PKG over the last 30 years. We are progressing toward the final stages
of completing our acquisition of PKG, Inc. and we believe that it is very important to communicate our commitment to all of you.
 
Cerebain Biotech is fully committed to a smooth transition and we look toward to continuing to support your existing business as well as providing
you with innovative products and technologies going forward.
 
As of today, we are 1argeting the completion of the acquisition of PKG by mid-November of- 2020.  After the transaction completes_ PKG will continue business
as a subsidiary of Cerebain Biotech Corp. under the name PKG. Inc. Cerebain Bio1ech Is dedicated to growing and building future business around the
existing PKG brand and utilizing its already developed infrastructure. Resources, Quality Management Systems (QMS), ISO Certifications, and internal processes.
 
About Cerebain Biotech Corp.
 
Cerebain Biotech (OTCQB: CBBT) is a development - stage medical device company focused on the creation and clinical development of a minimally invasive implantable device
and a synthetic drug solution. The device leverages the clinically observable, positive impact that Omentum stimulation has on cognitive function as related to dementias,
and in particular, Alzheimer's disease. The corporate vision is based on these positive clinical observations.
 
We are extremely excited by this opportunity and we thank you for your patience as we work diligently on finalizing this acquisition.

Sincerely,
Eric Clemons
CEO

https://twitter.com/CerebainBiotech/status/1315916488147050496

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

INSIDER FINANCIALL

October 15 2020 - OTC Markets Stock News

MOMENTUM & GROWTH

Cerebain Biotech (CBBT) PKG Deal A Game-Changer

Cerebain Biotech (CBBT) has turned into a monster runner and a massive win for our subscribers that got our alert in September. Most of our subscribers have averaged in around $.002
and saw a huge run to $.012 this month. While some have booked profits and taken some money off the table, there’s still a lot more room for CBBT to run before the New Year.

Cerebain Biotech Daily Chart

The reason for the big run is the acquisition of PKG Inc. by Cerebain Biotech. PKG was doing $21 million in revenues before COVID-19 hit. This year PKG is estimated to post around $14 million in revenues
and then return to pre-COVID levels next year. With the acquisition expected to close next month, this puts Cerebain Biotech on track to being a revenue leader on the OTC Markets. This also makes shares of CBBT awfully cheap
under a penny. In this article, we take a look at the bull case for Cerebain Biotech and why this bull run is just getting started for CBBT.

Read More -> https://insiderfinancial.com/cerebain-biotech-cbbt-pkg-deal-a-game-changer/180547/
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cerebain Biotech Announces General Business Update 

12 November 2020

COSTA MESA, Calif.--(BUSINESS WIRE)-- Cerebain Biotech Corp. (OTC: CBBT), (the “Company” or “Cerebain”) today announces a General Business Update.

Cerebain is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current.

Upon the completion of the acquisition, Cerebain will initiate a review of its overall business and corporate strategic plan. The corporate strategic initiatives to be developed and implemented include, but are not limited to, rebranding and repositioning of the Company’s overall business plan and a comprehensive growth strategy focused on revenue generation through a comprehensive roll-up acquisition strategy of target qualified candidates in select industries.

https://www.otcmarkets.com/stock/CBBT/news/story?e&id=1741596

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

PKG Acquisition; the Bull Run on Cerebain Biotech Corp OTCMKTS: CBBT)

 0
 
 Post Views: 1,638

Cerebain Biotech Corp OTCMKTS: CBBT) continues to rocket up the charts in recent days after the Company reported it is in the final stages of its acquisition of PKG, Inc. In combination with the closing of the acquisition of PKG, Cerebain intends to bring the Company’s SEC filings current. CBBT has skyrocketed up off its triple zero lows in August to recent highs of $0.025 per share. Microcapdaily first reported on Cerebain and PKG on October 7 when CBBT was trading at $0.003.

Read More here 

https://microcapdaily.com/pkg-acquisition-the-bull-run-on-cerebain-biotech-corp-otcmkts-cbbt/128629/
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cerebain Biotech Announces PKG, Inc. to Become Key Manufacturer for ClearMask™ and Xometry

See the person, not the mask. The first fully transparent, FDA-cleared mask produced in the United States is made possible through a manufacturing partnership between ClearMask LLC, Xometry, and PKG Inc. (Photo: Business Wire)

November 25, 2020 08:30 AM Eastern Standard Time

COSTA MESA, Calif.--(BUSINESS WIRE)--Cerebain Biotech Corp. (OTC: CBBT), today announced that PKG, Inc. is to become the key manufacturer for ClearMask, LLC and Xometry.

“We are proud to help ClearMask fight against the pandemic with a smile on our face that everyone can see. All of us are looking forward to successfully providing innovative accessibility and protection to a diverse population.”

http://See the person, not the mask. The first fully transparent, FDA-cleared mask produced in the United States is made possible through a manufacturing partnership between ClearMask LLC, Xometry, and PKG Inc. (Photo: Business Wire)
 
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 
 
AMT-abrev.png

Xometry helps ClearMask LLC produce and distribute millions of masks

Updated: Nov 20

In addition to facilitating the production of many different types of PPE, Maryland-based Xometry’s on-demand manufacturing marketplace was critical in enabling the production of an innovative transparent mask, ClearMask™, now available in both medical and non-medical versions in the marketplace at https://buy.theclearmask.com/.

Developed by ClearMask LLC, a Maryland-based medical company, the mask is a fully transparent, FDA-approved surgical mask that is essential for medical personnel and doctors who are deaf or hard of hearing and rely on facial expressions, visual cues, and lipreading to communicate. ClearMask blocks infectious particles and droplets through its transparent plastic barrier and has an anti-fog coating.

“ClearMask was approved by the FDA in April 2020, but the company was challenged with finding a manufacturer capable of producing and shipping very high volumes of the masks weekly,” said Greg Paulsen, director of application engineering, Xometry. “We identified a company in our global network of 5,000+ manufacturing suppliers who could produce and assemble millions of masks rapidly and cost effectively. We went beyond the role of supply chain partner and also served as a logistics expert and engineering consultant on this important project.”

Xometry is still managing and coordinating production between the ClearMask team and the supplying facility to ensure production goals are met. Millions of masks have been produced for medical personnel as well as state emergency management agencies, hospitals, essential workers, and different communities in need.

In addition to supporting those who work with deaf and hard of hearing individuals (worldwide there are more than 455 million people who are deaf), ClearMask is important for anyone who benefit from visual facial cues and full facial expressions. Apple, for example, has approved two masks for employee use. One mask is designed by Apple, and the other is ClearMask.
https://www.amtnews.org/post/xometry-helps-clearmask-llc-produce-and-distribute-millions-of-masks

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A very informative post https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159238893 that should be read

OTCShotCaller   Saturday, 10/31/20 09:36:12 PM
Re: None 0
Post #  of 20208 
 
Human Omentum - Cellular Basis For Tissue Re-generation

Apparently CBBT is in the process of harnessing the Human Omentum's known capacity for cellular regeneration, an already PROVEN FACT!

What this untapped area of Applied Biotechnology represents qualifies as "Disruptive Technology."

Human Omentum has been repeatedly shown to have the capacity to cause cellular regeneration & repair of various organs in the body including NEURONS!!! I posted several links on this yesterday 10/30/20 of several studies verifying the ability of human omentum to increase cerebral blood flow in brain tissue which in turn favors sustained neuron viability, and theoretically helps prevent the on-set or progress of Alzheimer's symptoms.

One study even showed that if arterial supply to a region of the brain is "tied off" by a surgeon, and then Human Omentum is placed over the area of the brain that the tied off artery supplied, the brain cells in that region of the brain continue to thrive as if the artery supply was never interrupted.

This finding is like something out of a science fiction movie, totally unheard of, totally unexplained, AND it likely represents one of the greatest scientific-medical discovery of modern medicine which CBBT has tapped into with the development of a viable and effective treatment for Alzheimer's.

Know this, Alzheimer's is all about brain cell (neurons) atrophy and death related to decreased blood flow to brain cell tissues with aging. Other mechanisms are involved but this is the primary cause. Nutrients also play a big role in neuron survival and thriving which human omentum highly supports because it's one of the richest nutrient sources in the human body.

Therefore with it's combined effect of causing increased blood flow brain cell tissue in tandem with delivery of high potency nutrients, these forces operating together have the capacity to preserve brain cell function in aging individuals.

This is what CBBT is up to in their Patent development for treating Alzheimer's and as a doctor I believe they are definitely on the right track.

Here's a very brief but major eye-opener video on this topic:

https://www.youtube.com/watch?v=4k7AZlYef_o

Be well and prosper ...

 

-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Funding Alzheimer’s research is as critical as fighting the stigma

Jan. 8, 2021 at 12:15 pm Updated Jan. 8, 2021 at 12:16 pm

https://www.seattletimes.com/opinion/funding-alzheimers-research-is-as-critical-as-fighting-the-stigma/

--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Institutional Holdings

 

A/S  1,250,000,000   05/13/2020

O/S    800,528,997   05/13/2021

Restricted 5,529,037  05/13/2021

Unrestricted 794,999,960  05/13/2021

Held At DTC  777,543,518  03/28/2021

Float   4,040,310    09/26/2018 ** See comment's below **

https://www.otcmarkets.com/stock/CBBT/security

The below Float number's cannot be verified, but as of the dates stated, that is what the individual website showed

Float per yahoo.Finance  139.81M  18 Oct 2020 https://finance.yahoo.com/quote/CBBT/key-statistics?p=CBBT
Float per TDA  138.2M 18 Oct 2020<a data-cke-saved-href="https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol="; href="https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol="; cbbt""="" rel="nofollow ugc" target="_blank">https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol="CBBT";"; rel="nofollow ugc" target="_blank">https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol=CBBT"; rel="nofollow ugc"> https://research.tdameritrade.com/grid/public/research/stocks/fundamentals?symbol=CBBT

 

PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#22130
From: "CEREBAIN BIOTECH INVESTOR RELATIONS DEPT." <ir@cerebain.com> TAB78 12/07/2020 03:40:05 PM
#32153
You bet. judypudy 06/29/2022 11:15:16 PM
#32152
Yeah ty TAB78 06/29/2022 06:00:41 PM
#32151
I think you were referring to this link? judypudy 06/17/2022 01:58:54 PM
#32150
Can you send me a link to where TAB78 06/17/2022 09:23:23 AM
#32149
Did not mean hating, typing from phone and TAB78 06/17/2022 09:11:00 AM
#32148
Not sure I understand your question? I judypudy 06/15/2022 11:59:05 PM
#32147
Judy what is the address you are TAB78 06/15/2022 07:46:09 PM
#32146
Interesting. I had the opposite reaction to the BubbaCheese 06/08/2022 11:04:19 AM
#32145
You’re correct. Everything lined up perfectly. I definitely Mavlo77 06/07/2022 02:08:54 PM
#32144
It was the perfect storm so to speak. OINGO BOINGO 06/06/2022 11:34:41 PM
#32143
True, and it's about the toughest lesson I TAB78 06/06/2022 02:33:58 PM
#32142
It's amazing, I agree with you 100% judypudy 06/03/2022 09:12:28 AM
#32141
Nothing we can do. There will be good Jack Torrance 06/02/2022 08:12:25 PM
#32140
Don't know what to say anymore TAB78 06/02/2022 07:25:09 PM
#32139
Judy, looks like a lot of folks are TAB78 06/02/2022 10:06:41 AM
#32138
If you read the exchange I posted with judypudy 06/01/2022 11:06:27 PM
#32137
Remember the "something will probably be announced next Jack Torrance 06/01/2022 06:45:39 PM
#32136
ANYTHING NEW?? ANYONE?? TAB78 06/01/2022 02:07:45 PM
#32135
whatever it is Cerebain has been very tight RMS555 05/13/2022 10:16:25 AM
#32134
Me neither. Not even sure where it would judypudy 05/13/2022 10:11:58 AM
#32133
9 days later and I still dont see RMS555 05/13/2022 09:30:36 AM
#32132
As to public companies going private I've been judypudy 05/08/2022 12:20:58 PM
#32131
Exactly, we'll put, they can however try to TAB78 05/08/2022 11:15:16 AM
#32130
Yep, but Alan was vague in what he TAB78 05/08/2022 11:09:54 AM
#32129
Excellent point that is very true. judypudy 05/08/2022 09:51:49 AM
#32128
$4,000,000 / .47 = 8,510,638 shares by my calculations. judypudy 05/08/2022 09:43:54 AM
#32127
Cerebain isn't private, they just aren't listed. To Jack Torrance 05/08/2022 09:10:37 AM
#32126
A private company with shareholders, in which shareholders TAB78 05/08/2022 08:30:05 AM
#32125
Yeah, I know, not saying it was exactly TAB78 05/08/2022 08:19:58 AM
#32124
K thanks TAB78 05/08/2022 08:16:31 AM
#32123
Wasn’t there a meeting with Eric and some Musicman99 05/08/2022 02:27:10 AM
#32122
Not sure how it could be insider trading judypudy 05/07/2022 11:18:21 PM
#32121
Is that not insider trading? Or no since Musicman99 05/07/2022 10:25:38 PM
#32120
I did a little DD and found a judypudy 05/07/2022 02:12:17 PM
#32119
Adam Woodall is admin of the Facebook page judypudy 05/07/2022 01:06:39 PM
#32118
So who is this from ??? Who TAB78 05/07/2022 11:19:06 AM
#32117
Well I appreciate you staying up to speed here, TAB78 05/07/2022 11:15:06 AM
#32116
LOL, I wouldn't hold your breath. Jack Torrance 05/06/2022 10:59:09 PM
#32115
Don't know about huge, but getting us trading judypudy 05/06/2022 12:02:17 PM
#32114
Ya sounds like Eric has something huge in Musicman99 05/06/2022 11:35:55 AM
#32113
Or there could be such a thing as judypudy 05/06/2022 11:30:09 AM
#32112
Gotcha. Its one thing if he has outside OINGO BOINGO 05/06/2022 11:03:55 AM
#32111
It appears it is Eric's phone number and judypudy 05/06/2022 09:59:00 AM
#32110
IMO it means other people are involved that judypudy 05/06/2022 09:53:57 AM
#32109
Exactly wth does he mean investing in the OINGO BOINGO 05/06/2022 01:09:59 AM
#32108
Can you explain what’s going on with these Musicman99 05/06/2022 01:04:34 AM
#32107
No guarantee that we will hear anything next judypudy 05/05/2022 11:05:18 AM
#32106
Thanks Judy! RMS555 05/05/2022 10:11:46 AM
#32105
The plot thickens! This indeed worthy of a BubbaCheese 05/05/2022 09:14:48 AM
#32104
Quite a nasty exchange. I am not holding Jack Torrance 05/04/2022 09:59:08 PM
Post Subject